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FDA Accepts AVMA
Recommendations on Extra-Label
Drug Use
On January 13, 1984, the Food and Drug
Administration's Bureau of Veterinary Medi-
cine (BVM) accepted recommendations from
the American Veterinary Medical Association
(AVMA) that allow veterinarians to use FDA-
approved drugs for extra-label purposes under
specific conditions.
The AVM.Ns recommendations were written
on December 15, 1983, by the ad hoc Commit-
tee on Extra-Label Use of Drugs. They were
adopted by the AVMXs Board of Governors on
January 5, 1984, and irnmediately sent to the
BVM.
The recommendations specify that when a
veterinarian-client-patient relationship exists,
veterinarians may prescribe or use FDA-
approved products in food-producing animals,
but only when the veterinarian has taken ap-
propriate steps to assure adequate identifica-
tion of treated animals and has provided for
extended withdrawal times when necessary.
The AVMA believes that the BVM's accept-
ance of the recommendations will quell the
controversy that resulted from the BVM's an-
nouncement last July of a more restrictive drug
use policy. Once again, veterinarians will have
the freedom to treat animals in a professional
manner.
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On January 13, 1984, Dr. Lester M. Craw-
ford, Director of FDXs Bureau of Veterinary
Medicine (BVM), notified the AVMA that the
agency agrees with AVMXs recommendations
for an enforcement policy regarding the use of
drugs in food-producing animals. BVM re-
sponded quickly to recommendations that had
been' adopted by AVM.Ns Board of Governors
on January 5. The AVMA recommendation
was accepted without modification.
In July, 1983, Dr. Crawford announced a
new enforcement policy intended to crack
down on a few "flagrant violators" who were
improperly providing drugs for use in food-
producing animals. Although BVM consistent-
ly maintained that the new policy was aimed
solely at a few individuals and companies, the
wording of the policy was such as to threaten
some generally accepted drug-use practices by
legitin1ate practicing veterinarians.
FDXs policy declared that no use of a drug
in a food animal will be tolerated if that use is
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not specified in the product's labeling. The pol-
icy applied to labeling limitations regarding
species, indications, and dosages, and it de-
clared that FDA would refrain from regulatory
action only in the most limited circun1stances.
A conference of veterinarians representing a
number of practice groups and spokesmen for
several livestock groups met under AVMA aus-
pices in late September to address the issue (see
ISU Veterinarian) 45:2, p.124). The purpose was
to seek a solution to the problem that BVM
had identified - but a solution that did not in-
terfere with the legitimate practice of veteri-
nary medicine. The group proposed that FDA
modify the policy to declare that extra-label use
of drugs in food-producing animals is only ap-
propriate if the drug is used in the context of a
bona fide veterinarian-client-patient relation-
ship. It was understood that the veterinarian
and client must assume responsibility for any
residues that enter the human food supply.
Despite a prompt rejection of the proposal
by BVM, the leadership of AVMA adopted the
policy in October, 1983, and appointed an ad
hoc committee to try again for a solution that
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would be acceptable to BVM and practi-
tioners. The issue continued to be a focus of
debate throughout the fall, and the ad hoc
committee developed a revised policy state-
ment at a meeting on December 15, 1983.
This is the statement that has now been ac-
cepted by AVMA and FDA as an appropriate
enforcement policy.
The key language of the policy statement,
identifying the problem and setting the stand-
ard of extra-label drug use, is as follows:
The Bureau of Veterinary Medicine has
found instances in which prescription veteri-
nary drugs have been distributed to non-veteri-
narians "by or on the order of a licensed veteri-
narian ," but this has taken place under
circun1stances that the Bureau believes are be-
yond the intended scope of "the course of the
(veterinarian's) professional practice." In other
instances, the Bureau has become aware of dis-
tribution of other drug substances not approved
for food animal use and the use of these drugs
in the absence of a veterinarian-client-patient
relationship.
The agency does not intend to interfere with
responsible veterinary practice where diagnosis
and treatment dictate drug therapy for a condi-
tion for which there is no approved drug or for
which approved drugs or dosages have been
found to be clinically ineffective. However,
scrupulous precautions shall be taken to main-
tain adequate identity of the treated animals
and to assure that appropriate, extended time
periods elapse before meat, milk, and eggs are
marketed for human food. The agency ack-
owledges, therefore, that the prudent use of
FDA-approved drugs for extra-label purposes is
necessary in the course of veterinary practice
within the framework of a bona fide veterinari-
an-client-patient relationship. Furthermore, the
agency will take necessary action to prevent,
stay, or curb the distribution and use of drugs
not approved for use in -food animals in the ab-
sence of a veterinarian-client-patient relation-
ship.
The policy statem~nt recognizes that a drug
should be used in food-producing animals only
under the supervision of a veterinarian if FDA
has not determined that it can be used safely.
This supervision requires the existence of a
bona fide veterinarian-client-patient relation-
ship, and that relationship, for the purposes of
federal food and drug law, is defined in the
policy statement.
Some of the implications of this policy state-
ment deserve to be higWighted:
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• AVMA supports the principle of the Food,
Drug, and Cosmetic Act that no drug should
be used unless it has FDA approval for some
purpose, although that approval may not be
for the use decided upon by the veterinarian.
• Veterinarians and livestock producers
should remember that any extra-label use of a
drug has the potential for greater liability than
a within-label use. An indication for use on a
label of an approved drug assures the user that
the drug sponsor and FDA have found, on the
basis of scientific evidence, that the use is safe
and effective, with side effects or adverse reac-
tions noted. In contrast, with an extra-label
use, the veterinarian is on his own to some
extent, and he is really on his own if there is
little support for his use of the drug within the
veterinary medical community.
• Nothing in the policy statement dimin-
ishes the veterinarian's or producer's potential
liability under federal laws for causing illegal
residues of drugs in human food.
• Good judgment must be applied in the in-
terpretation of the sentence that states, "How-
ever, scrupulous precautions shall be taken to
maintain adequate identity of the treated ani-
mals and to assure that appropriate, extended
time periods elapse before meat, milk, and eg-
gs are marketed for human food:' Reasonable,
effective means must be adopted to keep track
of any food animal or group of food animals
that receives drug therapy that has not been
approved by FDA. The "appropriate, extended
time period" prior to marketing requires a
medical judgment based on the nature of the
drug therapy and the condition of the animals.
All the discussions of drug use within the
veterinary profession and the livestock industry
have heightened the awareness of all parties of
the need for proper drug use in food-producing
animals. This has, in effect, been an educa-
tional activity, and Dr. Crawford urged AVMA
to continue to help its members use drugs wise-
ly. In a similar vein, USDP(s Food Safety and
Inspection Service has been working with the
Extension Service to develop informational
materials for producers as a part of the Residue
Avoidance Program (RAP). There is wide-
spread feeling that it will be much more effec-
tive to provide producers and veterinarians
with good information on avoiding drug and
chemical residues than to implement a strin-
gent (but necessarily selective) enforcement ef-
fort by FDA and USDA.
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